Atai life sciences announces the publication of beckley psytech's phase 1 study of bpl-003 in the journal of psychopharmacology

New york and berlin, april 17, 2024 (globe newswire) -- atai life sciences (nasdaq: atai) (“atai” or “company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the publication of the phase 1 results of bpl-003, beckley psytech's novel, synthetic, intranasal benzoate salt formulation of 5-meo-dmt, in the journal of psychopharmacology.
ATAI Ratings Summary
ATAI Quant Ranking